Market Overview

Goldman Sachs Sees 8% Upside At Dr. Reddy's

Goldman Sachs Sees 8% Upside At Dr. Reddy's
Related RDY
The Daily Biotech Pulse: Mylan Recalls Blood Pressure Drug, Heat Biologics Offering, New Novelion CEO
40 Biggest Movers From Yesterday
Generics under pressure on expanded price-fixing investigation (Seeking Alpha)

Goldman Sachs has started Dr.Reddy's Laboratories Ltd (ADR) (NYSE: RDY) with a Neutral rating; its price target of Rs.3,334.00 represents an upside of 8 percent.

"[W]e believe upside from current levels will depend more on when the company can resolve cGMP issues at warning letter plants (Srikakulam, Miryalaguda, Duvvuda; 12 percent–15 percent of FY16E sales), than on its pipeline in which launches have been consequently delayed," analyst Shyam Srinivasan wrote in a note.

Related Link: PrimaBioMed Jumps 10% As Company Receives Japanese Patent Grant

Notably, the analyst said the company's key generics, like gXeloda, gCopaxone and gGleevec (accounting for 4 percent of FY16E–FY19E sales), will now launch later than originally expected. According to Srinivasan, gGleevec, gXeloda, gZevavod and gDiprivan should collectively contribute above US$160 million in sales over FY17–FY18.

Although the analyst is "encouraged by the recent in-licensing of Ph II psoriasis molecule XP23829," he said, "There remain more hurdles to cross before commercialization, which should take at least two years from now, in a best-case scenario."

Moreover, the warning letter on the plants remains a key overhang on the stock, and the analyst said he expects a resolution could take until late FY17.

At time of writing, ADRs of Dr.Reddy's were down 1.73 percent to $44.81.

Latest Ratings for RDY

Nov 2017JefferiesMaintainsUnderperform
Sep 2017Morgan StanleyUpgradesEqual-WeightOverweight
Jul 2016HSBCDowngradesHoldReduce

View More Analyst Ratings for RDY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Emerging Markets Price Target Initiation Top Stories Markets Best of Benzinga


Related Articles (RDY)

View Comments and Join the Discussion!

Latest Ratings

CMAB. Riley FBRDowngrades84.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Here's How Baker Hughes Will Benefit From A Merger It Never Wanted In The First Place

Is Amazon Unstoppable? Gene Munster Thinks So